Corporate Sites

https://www.pfizer.com/

Contact for CT:

Julie Rogers

Field Reimbursement Manager

860-422-0420

julie.rogers@pfizer.com

Important News and Information

02/11/2025  Pfizer Oncology is pleased to share that on February 11, 2025, the FDA approved the 8^th indication for ADCETRIS® (brentuximab vedotin) in adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product. 

For more detailed information, please see the Full ADCETRIS Prescribing Information, including Boxed Warning.

01/07/2025  Pfizer Oncology is proud to announce the FDA approval of BRAFTOVI® (encorafenib) in a new indication as part of a combination regimen. The following information is available for State Society review:

• BRAFTOVI Full Prescribing Information including Medication Guide

Pfizer FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation 12/20/2024     BRAFTOVI Full Prescribing Information including Medication Guide